Glycosylation in cancer: Mechanisms and clinical implications

Nature Reviews Cancer

Volumn 15, Issue 9, 2015, Pages 540-555

  Pinho, Salomé S ^a   Reis, Celso A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; GLYCOCONJUGATE; POLYSACCHARIDE;

CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER THERAPY; CELL ADHESION; CELL INTERACTION; CELL METABOLISM; EXTRACELLULAR MATRIX; GLYCOBIOLOGY; GLYCOSYLATION; HUMAN; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY;

GLYCOCONJUGATES; GLYCOSYLATION; HUMANS; NEOPLASMS; POLYSACCHARIDES;

EID: 84940449986     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3982     Document Type: Review

References (220)

1. Fuster M. M., & Esko J. D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542 (2005
2. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl Acad. Sci. USA 99, 10231-10233 (2002
3. Reis C. A., Osorio H., Silva L., Gomes C., & David L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 63, 322-329 (2010
4. Taniguchi N., Hancock W., Lubman D. M., & Rudd P. M. The second golden age of glycomics: from functional glycomics to clinical applications. J. Proteome Res. 8, 425-426 (2009
5. Pinho S. S., et al. Gastric cancer: adding glycosylation to the equation. Trends Mol. Med. 19, 664-676 (2013
6. Freeze H. H. Understanding human glycosylation disorders: biochemistry leads the charge. J. Biol. Chem. 288, 6936-6945 (2013
7. Ohtsubo K., & Marth J. D. Glycosylation in cellular mechanisms of health and disease. Cell 126, 855-867 (2006
8. Varki A., et al. (eds) Essentials of Glycobiology 2nd edn (Cold Spring Harbor Laboratory Press, 2009
9. Cummings R. D. The repertoire of glycan determinants in the human glycome. Mol. Biosyst. 5, 1087-1104 (2009
10. Gabius H. J., Andre S., Jimenez-Barbero J., Romero A., & Solis D. From lectin structure to functional glycomics: principles of the sugar code. Trends Biochem. Sci. 36, 298-313 (2011
11. Moremen K. W., Tiemeyer M., & Nairn A. V. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13, 448-462 (2012
12. Bennett E. P., et al. Control of mucin-type O glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22, 736-756 (2012
13. Clausen H., & Bennett E. P. A family of UDP-GalNAc: polypeptide N acetylgalactosaminyl-transferases control the initiation of mucin-type O linked glycosylation. Glycobiology 6, 635-646 (1996
14. Brockhausen I., Yang J., Lehotay M., Ogata S., & Itzkowitz S. Pathways of mucin O glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated sialyl Tn antigen expression. Biol. Chem. 382, 219-232 (2001
15. Ma J., & Hart G. W. O GlcNAc profiling: from proteins to proteomes. Clin. Proteomics 11, 8 (2014
16. Luther K. B., & Haltiwanger R. S. Role of unusual O glycans in intercellular signaling. Int. J. Biochem. Cell Biol. 41, 1011-1024 (2009
17. Julien S., Bobowski M., Steenackers A., Le Bourhis X., & Delannoy P. How do gangliosides regulate RTKs signaling?. Cells 2, 751-767 (2013
18. Ladenson R. P., Schwartz S. O., & Ivy A. C. Incidence of the blood groups and the secretor factor in patients with pernicious anemia and stomach carcinoma. Am. J. Med. Sci. 217, 194-197 (1949
19. Hakomori S. I., & Murakami W. T. Glycolipids of hamster fibroblasts and derived malignant-transformed cell lines. Proc. Natl Acad. Sci. USA 59, 254-261 (1968
20. Feizi T. Carbohydrate antigens in human cancer. Cancer Surv. 4, 245-269 (1985
21. Holmes E. H., Ostrander G. K., Clausen H., & Graem N. Oncofetal expression of Lex carbohydrate antigens in human colonic adenocarcinomas. Regulation through type 2 core chain synthesis rather than fucosylation. J. Biol. Chem. 262, 11331-11338 (1987
22. Hakomori S., & Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers. J. Natl Cancer Inst. 71, 231-251 (1983
23. Marcos N. T., et al. ST6GalNAc I controls expression of sialyl Tn antigen in gastrointestinal tissues. Front. Biosci. (Elite Ed.) 3, 1443-1455 (2011
24. Julien S., et al. ST6GalNAc I expression in MDA MB 231 breast cancer cells greatly modifies their O glycosylation pattern and enhances their tumourigenicity. Glycobiology 16, 54-64 (2006
25. Kannagi R., Yin J., Miyazaki K., & Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomoris concepts revisited. Biochim. Biophys. Acta 1780, 525-531 (2008
26. Buckhaults P., Chen L., Fregien N., & Pierce M. Transcriptional regulation of N acetylglucosaminyltransferase V by the src oncogene. J. Biol. Chem. 272, 19575-19581 (1997
27. Hatano K., Miyamoto Y., Nonomura N., & Kaneda Y. Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF κB-dependent transcriptional control of α2,3 sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. Int. J. Cancer 129, 1838-1847 (2011
28. Pinho S. S., et al. Loss and recovery of Mgat3 and GnT-III Mediated E cadherin N glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. PLoS ONE 7, e33191 (2012
29. Schietinger A., et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314, 304-308 (2006
30. Aryal R. P., Ju T., & Cummings R. D. The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of T synthase. J. Biol. Chem. 285, 2456-2462 (2010
31. Kakugawa Y., et al. Up regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl Acad. Sci. USA 99, 10718-10723 (2002
32. Kumamoto K., et al. Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res. 61, 4620-4627 (2001
33. Kellokumpu S., Sormunen R., & Kellokumpu I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. FEBS Lett. 516, 217-224 (2002
34. Gill D. J., Chia J., Senewiratne J., & Bard F. Regulation of O glycosylation through Golgi to ER relocation of initiation enzymes. J. Cell Biol. 189, 843-858 (2010
35. Brockhausen I. Mucin-type O glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 7, 599-604 (2006
36. Marcos N. T., et al. Role of the human ST6GalNAc I and ST6GalNAc II in the synthesis of the cancer-associated sialyl Tn antigen. Cancer Res. 64, 7050-7057 (2004
37. Roth J., Wang Y., Eckhardt A. E., & Hill R. L. Subcellular localization of the UDP N acetyl-d galactosamine: polypeptide N acetylgalactosaminylt ransferase-mediated O glycosylation reaction in the submaxillary gland. Proc. Natl Acad. Sci. USA 91, 8935-8939 (1994
38. Sewell R., et al. The ST6GalNAc I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl Tn O glycan in human breast cancer. J. Biol. Chem. 281, 3586-3594 (2006
39. Christiansen M. N., et al. Cell surface protein glycosylation in cancer. Proteomics 14, 525-546 (2014
40. Arnold J. N., Saldova R., Hamid U. M., & Rudd P. M. Evaluation of the serum N linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8, 3284-3293 (2008
41. Kim Y. J., & Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J. 14, 569-576 (1997
42. DallOlio F., & Chiricolo M. Sialyltransferases in cancer. Glycoconj. J. 18, 841-850 (2001
43. Lise M., et al. Clinical correlations of α2,6 sialyltransferase expression in colorectal cancer patients. Hybridoma 19, 281-286 (2000
44. Amado M., Carneiro F., Seixas M., Clausen H., & Sobrinho-Simoes M. Dimeric sialyl Lex expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology 114, 462-470 (1998
45. Baldus S. E., et al. Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: Sialosyl-Lewisa, Sialosyl-Lewisx and sialosyl Tn. Tumour Biol. 19, 445-453 (1998
46. Rosen S. D., & Bertozzi C. R. The selectins and their ligands. Curr. Opin. Cell Biol. 6, 663-673 (1994
47. Nakamori S., et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res. 53, 3632-3637 (1993
48. Borsig L., et al. Heparin and cancer revisited: mechanistic connections involving platelets, P selectin, carcinoma mucins, and tumor metastasis. Proc. Natl Acad. Sci. USA 98, 3352-3357 (2001
49. Locker G. Y., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24, 5313-5327 (2006
50. Marrelli D., et al. Preoperative positivity of serum tumor markers is a strong predictor of hematogenous recurrence of gastric cancer. J. Surg. Oncol. 78, 253-258 (2001
51. Tanaka F., et al. Prognostic significance of polysialic acid expression in resected non-small cell lung cancer. Cancer Res. 61, 1666-1670 (2001
52. Falconer R. A., Errington R. J., Shnyder S. D., Smith P. J., & Patterson L. H. Polysialyltransferase: a new target in metastatic cancer. Curr. Cancer Drug Targets 12, 925-939 (2012
53. Todeschini A. R., Dos Santos J. N., Handa K., & Hakomori S. I. Ganglioside GM2 tetraspanin CD82 complex inhibits met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J. Biol. Chem. 282, 8123-8133 (2007
54. Carvalho A. S., et al. Differential expression of α 2,3 sialyltransferases and α 1,3/4 fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. Int. J. Biochem. Cell Biol. 42, 80-89 (2010
55. de Vries T., Knegtel R. M., Holmes E. H., & Macher B. A. Fucosyltransferases: structure/function studies. Glycobiology 11, 119R-128R (2001
56. Hiraiwa N., et al. Transactivation of the fucosyltransferase VII gene by human T cell leukemia virus type 1 Tax through a variant cAMP-responsive element. Blood 101, 3615-3621 (2003
57. Matsuura N., et al. Gene expression of fucosyl-and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E selectin, in human breast cancer. Int. J. Oncol. 12, 1157-1164 (1998
58. Holmes E. H., Hakomori S., & Ostrander G. K. Synthesis of type 1 and 2 lacto series glycolipid antigens in human colonic adenocarcinoma and derived cell lines is due to activation of a normally unexpressed β1→3N acetylglucosaminyltransferase. J. Biol. Chem. 262, 15649-15658 (1987
59. Marcos N. T., et al. Helicobacter pylori induces β3GnT5 in human gastric cell lines, modulating expression of the SabA ligand sialyl-Lewis x. J. Clin. Invest. 118, 2325-2336 (2008
60. Magalhaes A., et al. Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. Biochim. Biophys. Acta 1852, 1928-1939 (2015
61. Trinchera M., et al. The biosynthesis of the selectin-ligand sialyl Lewis x in colorectal cancer tissues is regulated by fucosyltransferase VI and can be inhibited by an RNA interference-based approach. Int. J. Biochem. Cell Biol. 43, 130-139 (2011
62. Liu Y. C., et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl Acad. Sci. USA 108, 11332-11337 (2011
63. Potapenko I. O., et al. Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol. Oncol. 4, 98-118 (2010
64. Hutchinson W. L., Du M. Q., Johnson P. J., & Williams R. Fucosyltransferases: differential plasma and tissue alterations in hepatocellular carcinoma and cirrhosis. Hepatology 13, 683-688 (1991
65. Sato Y., et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N. Engl. J. Med. 328, 1802-1806 (1993
66. Takahashi M., Kuroki Y., Ohtsubo K., & Taniguchi N. Core fucose and bisecting GlcNAc, the direct modifiers of the N glycan core: their functions and target proteins. Carbohydr. Res. 344, 1387-1390 (2009
67. Dennis J. W., Laferte S., Waghorne C., Breitman M. L., & Kerbel R. S. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236, 582-585 (1987
68. Di Lella S., et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 50, 7842-7857 (2011
69. Croci D. O., et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156, 744-758 (2014
70. Demetriou M., Nabi I. R., Coppolino M., Dedhar S., & Dennis J. W. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J. Cell Biol. 130, 383-392 (1995
71. Seberger P. J., & Chaney W. G. Control of metastasis by Asn-linked, β1-6 branched oligosaccharides in mouse mammary cancer cells. Glycobiology 9, 235-241 (1999
72. Guo H. B., et al. Specific posttranslational modification regulates early events in mammary carcinoma formation. Proc. Natl Acad. Sci. USA 107, 21116-21121 (2010
73. Granovsky M., et al. Suppression of tumor growth and metastasis in Mgat5 deficient mice. Nat. Med. 6, 306-312 (2000
74. Guo H., Nagy T., & Pierce M. Post-translational glycoprotein modifications regulate colon cancer stem cells and colon adenoma progression in Apcmin/+ mice through altered Wnt receptor signaling. J. Biol. Chem. 289, 31534-31549 (2014
75. Yoshimura M., Nishikawa A., Ihara Y., Taniguchi S., & Taniguchi N. Suppression of lung metastasis of B16 mouse melanoma by N acetylglucosaminyltransferase III gene transfection. Proc. Natl Acad. Sci. USA 92, 8754-8758 (1995
76. Zhao Y., et al. Branched N glycans regulate the biological functions of integrins and cadherins. FEBS J. 275, 1939-1948 (2008
77. Kudelka M. R., Ju T., Heimburg-Molinaro J., & Cummings R. D. Simple sugars to complex disease- mucin-type O glycans in cancer. Adv. Cancer Res. 126, 53-135 (2015
78. Berois N., et al. GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin. Chem. 59, 225-233 (2013
79. Gomes J., et al. Expression of UDP N acetyl-d galactosamine: polypeptide N acetylgalactosaminyltransferase 6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. J. Histochem. Cytochem. 57, 79-86 (2009
80. Gill D. J., et al. Initiation of GalNAc-type O glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness. Proc. Natl Acad. Sci. USA 110, E3152-E3161 (2013
81. Dalziel M., et al. The relative activities of the C2GnT1 and ST3Gal I glycosyltransferases determine O glycan structure and expression of a tumor-associated epitope on MUC1. J. Biol. Chem. 276, 11007-11015 (2001
82. Reis C. A., David L., Seixas M., Burchell J., & Sobrinho-Simoes M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int. J. Cancer 79, 402-410 (1998
83. Itzkowitz S., et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 100, 1691-1700 (1991
84. Radhakrishnan P., et al. Immature truncated O glycophenotype of cancer directly induces oncogenic features. Proc. Natl Acad. Sci. USA 111, E4066-E4075 (2014
85. Pinho S., et al. Biological significance of cancer-associated sialyl Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett. 249, 157-170 (2007
86. David L., Nesland J. M., Clausen H., Carneiro F., & Sobrinho-Simoes M. Simple mucin-type carbohydrate antigens (Tn, sialosyl Tn and T) in gastric mucosa, carcinomas and metastases. APMIS Suppl. 27, 162-172 (1992
87. DallOlio F., Malagolini N., Trinchera M., & Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front. Biosci. (Landmark Ed.) 17, 670-699 (2012
88. Ferreira J. A., et al. Overexpression of tumour-associated carbohydrate antigen sialyl Tn in advanced bladder tumours. Mol. Oncol. 7, 719-731 (2013
89. Ricardo S., et al. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol. Oncol. 9, 503-512 (2015
90. Ju T., & Cummings R. D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3 galactosyltransferase. Proc. Natl Acad. Sci. USA 99, 16613-16618 (2002
91. Ju T., et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 68, 1636-1646 (2008
92. Julien S., et al. Sialyl Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 100, 1746-1754 (2009
93. Sandmaier B. M., et al. Evidence of a cellular immune response against sialyl Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J. Immunother. 22, 54-66 (1999
94. Pinho S. S., et al. E cadherin and adherens-junctions stability in gastric carcinoma: functional implications of glycosyltransferases involving N glycan branching biosynthesis, N acetylglucosaminyltransferases III and V. Biochim. Biophys. Acta 1830, 2690-2700 (2013
95. Pinho S. S., et al. The role of N acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E cadherin. Hum. Mol. Genet. 18, 2599-2608 (2009
96. Takeuchi H., & Haltiwanger R. S. Significance of glycosylation in Notch signaling. Biochem. Biophys. Res. Commun. 453, 235-242 (2014
97. Boscher C., Dennis J. W., & Nabi I. R. Glycosylation, galectins and cellular signaling. Curr. Opin. Cell Biol. 23, 383-392 (2011
98. de Freitas-Junior J. C., et al. Insulin/IGF I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N glycans modulation. an interplay with E cadherin. PLoS ONE 8, e81579 (2013
99. Gomes C., et al. Expression of ST3GAL4 leads to SLex expression and induces c Met activation and an invasive phenotype in gastric carcinoma cells. PLoS ONE 8, e66737 (2013
100. Dennis J. W., Nabi I. R., & Demetriou M. Metabolism, cell surface organization, and disease. Cell 139, 1229-1241 (2009
101. Bassaganas S., et al. Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of α2β1 integrin and E cadherin function. PLoS ONE 9, e98595 (2014
102. Helenius A., & Aebi M. Intracellular functions of N linked glycans. Science 291, 2364-2369 (2001
103. Pinho S. S., et al. Modulation of E cadherin function and dysfunction by N glycosylation. Cell. Mol. Life Sci. 68, 1011-1020 (2011
104. Paredes J., et al. Epithelial E-and P cadherins: role and clinical significance in cancer. Biochim. Biophys. Acta 1826, 297-311 (2012
105. Liwosz A., Lei T., & Kukuruzinska M. A. N glycosylation affects the molecular organization and stability of E cadherin junctions. J. Biol. Chem. 281, 23138-23149 (2006
106. Guo H. B., Lee I., Kamar M., & Pierce M. N acetylglucosaminyltransferase V expression levels regulate cadherin-associated homotypic cell-cell adhesion and intracellular signaling pathways. J. Biol. Chem. 278, 52412-52424 (2003
107. Ihara S., et al. Prometastatic effect of N acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching. J. Biol. Chem. 277, 16960-16967 (2002
108. Carvalho S., et al. Preventing E cadherin aberrant N glycosylation at Asn 554 improves its critical function in gastric cancer. Oncogene http://dx.doi. org/10.1038/onc.2015.225 (2015
109. Yoshimura M., Ihara Y., Matsuzawa Y., & Taniguchi N. Aberrant glycosylation of E cadherin enhances cell-cell binding to suppress metastasis. J. Biol. Chem. 271, 13811-13815 (1996
110. Kitada T., et al. The addition of bisecting N acetylglucosamine residues to E cadherin down-regulates the tyrosine phosphorylation of beta-catenin. J. Biol. Chem. 276, 475-480 (2001
111. Xu Q., et al. Roles of N acetylglucosaminyltransferase III in epithelial-to mesenchymal transition induced by transforming growth factor β1 (TGF β1) in epithelial cell lines. J. Biol. Chem. 287, 16563-16574 (2012
112. Gu J., et al. A mutual regulation between cell-cell adhesion and N glycosylation: implication of the bisecting GlcNAc for biological functions. J. Proteome Res. 8, 431-435 (2009
113. Dennis J. W., Granovsky M., & Warren C. E. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta 1473, 21-34 (1999
114. Pinho S. S., Reis C. A., Gartner F., & Alpaugh M. L. Molecular plasticity of E cadherin and sialyl lewis x expression, in two comparative models of mammary tumorigenesis. PLoS ONE 4, e6636 (2009
115. Seidenfaden R., Krauter A., Schertzinger F., Gerardy-Schahn R., & Hildebrandt H. Polysialic acid directs tumor cell growth by controlling heterophilic neural cell adhesion molecule interactions. Mol. Cell. Biol. 23, 5908-5918 (2003
116. Lin S., Kemmner W., Grigull S., & Schlag P. M. Cell surface α2,6 sialylation affects adhesion of breast carcinoma cells. Exp. Cell Res. 276, 101-110 (2002
117. Tamura F., et al. RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. Gastric Cancer http://dx.doi. org/10.1007/s10120-014-0454-z (2014
118. Kim S. H., Turnbull J., & Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 209, 139-151 (2011
119. Sarrazin S., Lamanna W. C., & Esko J. D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 3, a004952 (2011
120. Wade A., et al. Proteoglycans and their roles in brain cancer. FEBS J. 280, 2399-2417 (2013
121. Cecchi F., et al. Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell 22, 250-262 (2012
122. Tan K. W., et al. Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF A bioavailability and secreting VEGF D. Blood 122, 3666-3677 (2013
123. Gunthert U., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991
124. da Cunha C. B., et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab. Invest. 90, 1604-1614 (2010
125. English N. M., Lesley J. F., & Hyman R. Site-specific de N glycosylation of CD44 can activate hyaluronan binding, and CD44 activation states show distinct threshold densities for hyaluronan binding. Cancer Res. 58, 3736-3742 (1998
126. Katoh S., Zheng Z., Oritani K., Shimozato T., & Kincade P. W. Glycosylation of CD44 negatively regulates its recognition of hyaluronan. J. Exp. Med. 182, 419-429 (1995
127. Goupille C., Hallouin F., Meflah K., & Le Pendu J. Increase of rat colon carcinoma cells tumorigenicity by α(1-2) fucosyltransferase gene transfection. Glycobiology 7, 221-229 (1997
128. Wolff E. A., et al. Generation of artificial proteoglycans containing glycosaminoglycan-modified CD44. Demonstration of the interaction between rantes and chondroitin sulfate. J. Biol. Chem. 274, 2518-2524 (1999
129. Roucourt B., Meeussen S., Bao J., Zimmermann P., & David G. Heparanase activates the syndecan-syntenin-ALIX exosome pathway. Cell Res. 25, 412-428 (2015
130. Bharadwaj A. G., et al. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am. J. Pathol. 174, 1027-1036 (2009
131. Paszek M. J., et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 511, 319-325 (2014
132. Liotta L. A. Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46, 1-7 (1986
133. Jin H., & Varner J. Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90, 561-565 (2004
134. Asada M., Furukawa K., Segawa K., Endo T., & Kobata A. Increased expression of highly branched N glycans at cell surface is correlated with the malignant phenotypes of mouse tumor cells. Cancer Res. 57, 1073-1080 (1997
135. Guo H. B., Lee I., Kamar M., Akiyama S. K., & Pierce M. Aberrant N glycosylation of β1 integrin causes reduced α5β1 integrin clustering and stimulates cell migration. Cancer Res. 62, 6837-6845 (2002
136. Pochec E., et al. Expression of integrins α3β1 and α5β1 and GlcNAc β1,6 glycan branching influences metastatic melanoma cell migration on fibronectin. Eur. J. Cell Biol. 92, 355-362 (2013
137. Isaji T., et al. Introduction of bisecting GlcNAc into integrin α5β1 reduces ligand binding and down-regulates cell adhesion and cell migration. J. Biol. Chem. 279, 19747-19754 (2004
138. Zhao Y., et al. N acetylglucosaminyltransferase III antagonizes the effect of N acetylglucosaminyltransferase V on α3β1 integrin-mediated cell migration. J. Biol. Chem. 281, 32122-32130 (2006
139. Gu J., & Taniguchi N. Regulation of integrin functions by N glycans. Glycoconj. J. 21, 9-15 (2004
140. Dennis J., Waller C., Timpl R., & Schirrmacher V. Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature 300, 274-276 (1982
141. Seales E. C., et al. Hypersialylation of β1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up regulating cell motility. Cancer Res. 65, 4645-4652 (2005
142. Kariya Y., Kawamura C., Tabei T., & Gu J. Bisecting GlcNAc residues on laminin 332 down-regulate galectin 3 dependent keratinocyte motility. J. Biol. Chem. 285, 3330-3340 (2010
143. Ranjan A., Bane S. M., & Kalraiya R. D. Glycosylation of the laminin receptor (α3β1) regulates its association with tetraspanin CD151: impact on cell spreading, motility, degradation and invasion of basement membrane by tumor cells. Exp. Cell Res. 322, 249-264 (2014
144. Vlodavsky I., & Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 108, 341-347 (2001
145. Lendorf M. E., Manon-Jensen T., Kronqvist P., Multhaupt H. A., & Couchman J. R. Syndecan 1 and syndecan 4 are independent indicators in breast carcinoma. J. Histochem. Cytochem. 59, 615-629 (2011
146. Saoncella S., et al. Syndecan 4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers. Proc. Natl Acad. Sci. USA 96, 2805-2810 (1999
147. Beauvais D. M., Burbach B. J., & Rapraeger A. C. The syndecan 1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cells. J. Cell Biol. 167, 171-181 (2004
148. Warburg O. On the origin of cancer cells. Science 123, 309-314 (1956
149. Marshall S., Bacote V., & Traxinger R. R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J. Biol. Chem. 266, 4706-4712 (1991
150. Wells L., Vosseller K., & Hart G. W. Glycosylation of nucleocytoplasmic proteins: signal transduction and O GlcNAc. Science 291, 2376-2378 (2001
151. Slawson C., Copeland R. J., & Hart G. W. O GlcNAc signaling: a metabolic link between diabetes and cancer?. Trends Biochem. Sci. 35, 547-555 (2010
152. Ferrer C. M., et al. O GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF 1 pathway. Mol. Cell 54, 820-831 (2014
153. Ma Z., & Vosseller K. Cancer metabolism and elevated O GlcNAc in oncogenic signaling. J. Biol. Chem. 289, 34457-34465 (2014
154. Caldwell S. A., et al. Nutrient sensor O GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 29, 2831-2842 (2010
155. Zachara N. E., & Hart G. W. Cell signaling, the essential role of O GlcNAc Biochim. Biophys. Acta 1761, 599-617 (2006
156. Lynch T. P., et al. Critical role of O linked β N acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J. Biol. Chem. 287, 11070-11081 (2012
157. Zhu W., Leber B., & Andrews D. W. Cytoplasmic O glycosylation prevents cell surface transport of E cadherin during apoptosis. EMBO J. 20, 5999-6007 (2001
158. Hart G. W., Slawson C., Ramirez-Correa G., & Lagerlof O. Cross talk between O GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 80, 825-858 (2011
159. Itkonen H. M., et al. O GlcNAc transferase integrates metabolic pathways to regulate the stability of c MYC in human prostate cancer cells. Cancer Res. 73, 5277-5287 (2013
160. Yang W. H., et al. Modification of p53 with O linked N acetylglucosamine regulates p53 activity and stability. Nat. Cell Biol. 8, 1074-1083 (2006
161. Lau K. S., et al. Complex N glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129, 123-134 (2007
162. Stanley P. A method to the madness of N glycan complexity?. Cell 129, 27-29 (2007
163. Taniguchi N. A sugar-coated switch for cellular growth and arrest. Nat. Chem. Biol. 3, 307-309 (2007
164. Partridge E. A., et al. Regulation of cytokine receptors by Golgi N glycan processing and endocytosis. Science 306, 120-124 (2004
165. Guo H. B., Johnson H., Randolph M., Lee I., & Pierce M. Knockdown of GnT Va expression inhibits ligand-induced downregulation of the epidermal growth factor receptor and intracellular signaling by inhibiting receptor endocytosis. Glycobiology 19, 547-559 (2009
166. Song Y., Aglipay J. A., Bernstein J. D., Goswami S., & Stanley P. The bisecting GlcNAc on N glycans inhibits growth factor signaling and retards mammary tumor progression. Cancer Res. 70, 3361-3371 (2010
167. Sato Y., et al. Overexpression of N acetylglucosaminyltransferase III enhances the epidermal growth factor-induced phosphorylation of ERK in HeLaS3 cells by up regulation of the internalization rate of the receptors. J. Biol. Chem. 276, 11956-11962 (2001
168. Bremer E. G., & Hakomori S. Gangliosides as receptor modulators. Adv. Exp. Med. Biol. 174, 381-394 (1984
169. Park S. Y., Yoon S. J., Freire-de Lima L., Kim J. H., & Hakomori S. I. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells. Carbohydr. Res. 344, 1479-1486 (2009
170. Birks S. M., et al. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma. Neuro Oncol. 13, 950-960 (2011
171. Rabinovich G. A., & Toscano M. A. Turning sweet on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9, 338-352 (2009
172. Macauley M. S., Crocker P. R., & Paulson J. C. Siglec-mediated regulation of immune cell function in disease. Nat. Rev. Immunol. 14, 653-666 (2014
173. Ragupathi G., et al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J. Immunol. 174, 5706-5712 (2005
174. Lavrsen K., et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj. J. 30, 227-236 (2013
175. Samsen A., et al. DC SIGN and SRCL bind glycans of carcinoembryonic antigen (CEA) and CEA-related cell adhesion molecule 1 (CEACAM1): recombinant human glycan-binding receptors as analytical tools. Eur. J. Cell Biol. 89, 87-94 (2010
176. Saeland E., et al. The C type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol. Immunother. 56, 1225-1236 (2007
177. Laubli H., et al. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33 related Siglecs. J. Biol. Chem. 289, 33481-33491 (2014
178. Liu F. T., & Rabinovich G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29-41 (2005
179. Thijssen V. L., Heusschen R., Caers J., & Griffioen A. W. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim. Biophys. Acta 1855, 235-247 (2015
180. Dalziel M., Crispin M., Scanlan C. N., Zitzmann N., & Dwek R. A. Emerging principles for the therapeutic exploitation of glycosylation. Science 343, 1235681 (2014
181. Slovin S. F., et al. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA 96, 5710-5715 (1999
182. Buskas T., Thompson P., & Boons G. J. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem Commun. 2009, 5335-5349 (2009
183. Li M., Song L., & Qin X. Glycan changes: cancer metastasis and anti-cancer vaccines. J. Biosci. 35, 665-673 (2010
184. Beatson R. E., Taylor-Papadimitriou J., & Burchell J. M. MUC1 immunotherapy. Immunotherapy 2, 305-327 (2010
185. Mackall C. L., Merchant M. S., & Fry T. J. Immune-based therapies for childhood cancer. Nat. Rev. Clin. Oncol. 11, 693-703 (2014
186. Liu S. D., et al. Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol. Res. 3, 173-183 (2015
187. Gilgunn S., Conroy P. J., Saldova R., Rudd P. M., & OKennedy R. J. Aberrant PSA glycosylation - a sweet predictor of prostate cancer. Nat. Rev. Urol. 10, 99-107 (2013
188. Zurawski V. R. Jr, Orjaseter H., Andersen A., & Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer 42, 677-680 (1988
189. Goldstein M. J., & Mitchell E. P. Carcinoembryonic antigen in the staging and follow up of patients with colorectal cancer. Cancer Invest. 23, 338-351 (2005
190. Ebeling F. G., et al. Serum CEA and CA 15-13 as prognostic factors in primary breast cancer. Br. J. Cancer 86, 1217-1222 (2002
191. Kumpulainen E. J., Keskikuru R. J., & Johansson R. T. Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer. Breast Cancer Res. Treat. 76, 95-102 (2002
192. Safi F., Schlosser W., Kolb G., & Beger H. G. Diagnostic value of CA 19-19 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J. Gastrointest. Surg. 1, 106-112 (1997
193. Fukushima K., Satoh T., Baba S., & Yamashita K. α1,2 fucosylated and β N acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 20, 452-460 (2010
194. Jankovic M. M., & Milutinovic B. S. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark. 4, 35-42 (2008
195. Saeland E., et al. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int. J. Cancer 131, 117-128 (2012
196. Noda K., et al. Gene expression of α1 6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of α-fetoprotein. Hepatology 28, 944-952 (1998
197. Wang M., et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev. 18, 1914-1921 (2009
198. Adamczyk B., Tharmalingam T., & Rudd P. M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 1820, 1347-1353 (2012
199. Steentoft C., et al. Mining the O glycoproteome using zinc-finger nuclease-glycoengineered SimpleCell lines. Nat. Methods 8, 977-982 (2011
200. Campos D., et al. Probing the O glycoproteome of gastric cancer cell lines for biomarker discovery. Mol. Cell. Proteomics 14, 1616-1629 (2015
201. Lauc G., et al. Genomics meets glycomics - the first GWAS study of human N glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet. 6, e1001256 (2010
202. Miyoshi E., & Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 8, 3257-3262 (2008
203. Gomes C., et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J. Proteome Res. 12, 1454-1466 (2013
204. Saldova R., Fan Y., Fitzpatrick J. M., Watson R. W., & Rudd P. M. Core fucosylation and α2 3 sialylation in serum N glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology 21, 195-205 (2011
205. Melo S. A., et al. Glypican 1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523, 177-182 (2015
206. Blixt O., et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res. 13, R25 (2011
207. Pedersen J. W., et al. Cancer-associated autoantibodies to MUC1 and MUC4 - a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int. J. Cancer 134, 2180-2188 (2014
208. Moloney D. J., et al. Mammalian Notch1 is modified with two unusual forms of O linked glycosylation found on epidermal growth factor-like modules. J. Biol. Chem. 275, 9604-9611 (2000
209. Panin V. M., Papayannopoulos V., Wilson R., & Irvine K. D. Fringe modulates Notch-ligand interactions. Nature 387, 908-912 (1997
210. Cohen B., et al. Fringe boundaries coincide with Notch-dependent patterning centres in mammals and alter Notch-dependent development in Drosophila. Nat. Genet. 16, 283-288 (1997
211. Tanaka H., et al. Acute myelogenous leukemia with PIG A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome. Int. J. Hematol. 73, 206-212 (2001
212. Ilver D., et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 279, 373-377 (1998
213. Mahdavi J., et al. Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 297, 573-578 (2002
214. Magalhaes A., Ismail M. N., & Reis C. A. Sweet receptors mediate the adhesion of the gastric pathogen Helicobacter pylori: glycoproteomic strategies. Expert Rev. Proteomics 7, 307-310 (2010
215. Sarrats A., et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin. Appl. 4, 432-448 (2010
216. Dias A. M., et al. Dysregulation of T cell receptor N glycosylation: a molecular mechanism involved in ulcerative colitis. Hum. Mol. Genet. 23, 2416-2427 (2014
217. Samraj A. N., et al. A red meat-derived glycan promotes inflammation and cancer progression. Proc. Natl Acad. Sci. USA 112, 542-547 (2015
218. Chou H. H., et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl Acad. Sci. USA 95, 11751-11756 (1998
219. Ychou M., Duffour J., Kramar A., Gourgou S., & Grenier J. Clinical significance and prognostic value of CA72 4 compared with CEA and CA19 9 in patients with gastric cancer. Dis. Markers 16, 105-110 (2000
220. Valmu L., Alfthan H., Hotakainen K., Birken S., & Stenman U. H. Site-specific glycan analysis of human chorionic gonadotropin β-subunit from malignancies and pregnancy by liquid chromatography - electrospray mass spectrometry. Glycobiology 16, 1207-1218 (2006